Chilworth, UK – 23 September 2009 – Karus Therapeutics Ltd, a company developing small molecule drugs to treat cancer and inflammation, has today announced that it has signed an agreement to collaborate with Professor Bart Vanhaesebroeck, at Queen Mary, University of London. Prof. Vanhaesebroeck is Centre Lead of the RAE 4-star rated Cell Signalling Laboratory. […]
Chilworth, UK – 17 August 2009 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that the company’s CSO, Dr Stephen Shuttleworth, will be making presentations at three key conferences in the coming weeks. In September, Dr Shuttleworth will be speaking at the Bio2Business meeting in London, UK. His presentation, entitled “Lead optimization strategies: […]
Chilworth, UK – 1 June 2009 – Innovative pharmaceutical company Karus Therapeutics has today announced a collaborative research program with the Queen Elizabeth Hospital Renal Transplant Unit under the supervision of Lead Surgeon, Andrew Ready, Consultant Surgeon, Nicholas Inston, and Stephen Shuttleworth, CSO of Karus. The research program is designed to investigate the in vitro mechanisms-of-action of […]
Chilworth, UK – 4 May 2009 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the successful receipt of a Knowledge Transfer Partnership (KTP) award with King’s College London. The award will be used to support a collaborative program at the internationally renowned St John’s Institute of Dermatology at Guy’s Hospital under the joint […]
Chilworth, UK – 6 April 2009 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced a second closing of its December 2008 investment, bringing the total amount raised to over £1 million and securing the company’s first US-based investor, New Hill Management LLC. “Bringing a new investor to Karus is a tremendous achievement in […]
Southampton, UK – 7 January 2009 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.9 million investment. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of Business Angels. The investment will be used to advance the development of new drugs to treat cancer and inflammatory diseases […]
Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Prog Med Chem. 2009, 48, p81-131.